Changes in Biochemical Parameters of the Calcium-Phosphorus Homeostasis in Relation to Nutritional Intake in Very-Low-Birth-Weight Infants by Christmann, V. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/168742
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
nutrients
Article
Changes in Biochemical Parameters of the
Calcium-Phosphorus Homeostasis in Relation to
Nutritional Intake in Very-Low-Birth-Weight Infants
Viola Christmann 1,*, Charlotte J. W. Gradussen 1, Michelle N. Körnmann 1, Nel Roeleveld 2,3,
Johannes B. van Goudoever 4,5 and Arno F. J. van Heijst 1
1 Department of Paediatrics, Subdivision of Neonatology, Radboudumc Amalia Children’s Hospital,
Radboud University Medical Center, Nijmegen 6500HB, The Netherlands;
charlotte.gradussen@radboudumc.nl (C.J.W.G.); michelle.kornmann@radboudumc.nl (M.N.K.);
arno.vanheijst@radboudumc.nl (A.F.J.v.H.)
2 Department for Health Evidence, Radboud Institute for Health Science, Radboud University Medical Center,
Nijmegen 6500HB, The Netherlands; nel.roeleveld@radboudumc.nl
3 Department of Paediatrics, Radboudumc Amalia Children’s Hospital, Radboud University Medical Center,
Nijmegen 6500HB, The Netherlands
4 Department of Paediatrics, VU university medical center Amsterdam, Amsterdam 1081HV,
The Netherlands; h.vangoudoever@vumc.nl
5 Department of Paediatrics, Emma Children’s Hospital-AMC Amsterdam, Amsterdam 1105AZ,
The Netherlands
* Correspondence: viola.christmann@radboudumc.nl; Tel.: +31-243-614-430
Received: 14 September 2016; Accepted: 24 November 2016; Published: 29 November 2016
Abstract: Preterm infants are at significant risk to develop reduced bone mineralization based on
inadequate supply of calcium and phosphorus (Ca-P). Biochemical parameters can be used to evaluate
the nutritional intake. The direct effect of nutritional intake on changes in biochemical parameters has
not been studied. Our objective was to evaluate the effect of Ca-P supplementation on biochemical
markers as serum (s)/urinary (u) Ca and P; alkaline phosphatase (ALP); tubular reabsorption of P
(TrP); and urinary ratios for Ca/creatinin (creat) and P/creatinin in Very-Low-Birth-Weight infants
on Postnatal Days 1, 3, 5, 7, 10, and 14. This observational study compared two groups with High
(n = 30) and Low (n = 40) intake of Ca-P. Birth weight: median (IRQ) 948 (772–1225) vs. 939 (776–1163)
grams; and gestational age: 28.2 (26.5–29.6) vs. 27.8 (26.1–29.4) weeks. Daily median concentrations
of biochemical parameter were not different between the groups but linear regression mixed model
analyses showed that Ca intake increased the uCa and TrP (p = 0.04) and decreased ALP (p = 0.00).
Phosphorus intake increased sP, uP and uP/creat ratio and ALP (p ≤ 0.02) and caused decrease
in TrP (p = 0.00). Protein intake decreased sP (p = 0.000), while low gestational age and male
gender increased renal excretion of P (p < 0.03). Standardized repeated measurements showed that
biochemical parameters were affected by nutritional intake, gestational age and gender.
Keywords: blood; bone mineralization; minerals; monitoring; nutrition; renal tubular reabsorption;
supplementation; urine
1. Introduction
Bone development is one of the key processes of intrauterine and postnatal growth [1]. Preterm
infants are at significant risk to develop reduced bone mineral content based on inadequate supply of
calcium and phosphorus (Ca-P) [2,3]. During normal pregnancies in healthy mothers, there is an active,
placental transfer of Ca-P to the fetus leading to a high mineral accretion during the last trimester,
while after birth the infant is dependent on nutritional supply of minerals [4,5]. In clinical practice,
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postnatally it is difficult to meet the high fetal needs, because of limited solubility of parenteral fluids,
low content of Ca-P of human milk and impaired intestinal absorption through formula feeding [6–9].
Studies tried to define nutritional requirements, but, in clinical practice, it is often uncertain whether
the nutritional intake of Ca-P provided to preterm infants is sufficient and is actually used for bone
mineralization [10–12].
Assuming that biochemical parameters of Ca-P homeostasis within a normal range will lead
to optimal bone mineralization, evaluation of electrolyte disturbances is standard of care in many
neonatal units [13–28]. However, there is currently neither a consensus on the appropriateness of
either parameter or the frequency of measurements [29,30]. A recent survey among U.S. neonatologists
showed a great lack of consensus and variation in practices regarding definition and screening methods
for metabolic bone disease [31]. Reference values in relation to adequate nutritional intake have not
been developed. Urinary excretion of minerals in spot urine samples has been shown to be an easy
tool for routine evaluation. Pohlandt proposed to aim for a small “surplus of minerals” in urine
samples, while Aladangady et al. developed reference values for urinary Ca-P/creatinine ratios for
preterm infants [17,23]. Staub et al. compared both methods with regard to an agreement between their
results and found neither method to be superior [32]. None of the studies evaluated the direct effect of
nutritional intake on biochemical parameter of Ca-P homeostasis. It is not sure whether biochemical
parameters are able to indicate sufficiency of nutritional intake.
The aim of this study was to evaluate changes in biochemical parameters of the Ca-P homeostasis
in blood and urine in relation to different nutritional intake during the first 14 days of life in Very
Low Birth Weight (VLBW) infants. Our hypothesis was that the nutritional intake of calcium and
phosphorus would have an effect on biochemical parameters of the calcium–phosphorus homeostasis.
2. Materials and Methods
2.1. Study Design and Randomization
The current study (Early Supplementation Study (ESS)) was part of the Early Nutrition Study
(ENS), a multi-center double-blinded randomized controlled trial.While the ENS evaluated the effects
of human milk on postnatal outcome, the primary objective of the ESS was bone mineralization in
relation to early and late enteral supplementation of minerals [33]. The studies were approved by the
Ethical Committee of the VU university medical center (Amsterdam, The Netherlands), 13 September
2013 (CMO file number: NL37296.029.11, Dutch Trial Registry: NTR 3225). Patients were distributed
into three groups through two steps of randomization. The first step randomized eligible infants either
into the early supplementation group (High) or the late supplementation group (Low) being part
of the ENS. The second step of the randomization was only performed if infants were assigned to
late supplementation and randomized them to either “ENS A” or “ENS B” as part of the ENS. Both
randomization steps were performed before the first enteral nutrition was administered resulting in
basically three groups.
2.2. Study Population
Participants for the ENS/ESS were recruited at the level III neonatal intensive care unit of the
Radboud university medical center (Radboudumc), Nijmegen, The Netherlands. The inclusion criteria
were a birth weight below 1500 grams and written informed consent of both parents. The exclusion
criteria were maternal drugs and/or alcohol use during pregnancy, birth defects, congenital infection
within 72 h after birth, perinatal asphyxia with a pH < 7.0 and any intake of cow’s milk based products
prior to randomization. For the current study, infants who died or were discharged before the end of
the study period of 14 days were excluded from analysis.
Nutrients 2016, 8, 764 3 of 17
2.3. Intervention and Nutritional Protocol
Parenteral nutrition (PN) was started directly within the first hour after birth. The PN
solution consisted of 2.5 mmol/dL calcium-gluconate (calcium-gluconate 10%; B. Braun, Melsungen,
Germany) and 1.6 mmol/dL sodium-glycerophosphate (Glycophos; Fresenius Kabi BV, Zeist,
The Netherlands) and 2.25 grams/dL amino acids (Primene; Clintec, Brussels). Additional parenteral
supplementation with 10% calcium-gluconate or sodium glycero-phosphate was administrated
depending on biochemical parameters. Table A1 presents the standard protocol for PN. The decision
to start additional supplementation was left to the attending neonatologist based on biochemical
parameter as being a standard procedure of our department.
Enteral feeding was started on the first day of life with daily increments, while PN was gradually
reduced to maintain a daily fluid intake within the protocol range. Late supplementation was assumed
to provide a low intake of nutrients because “Group Low”, comprising of group ENS A and ENS B,
received no additional enteral supplementation or fortification of human milk during the first 10 days
of life. Group ENS A received donor milk if mother’s own milk (MOM) was not available. Group ENS B
received preterm formula (Hero Baby Prematuur Start; Hero Kindervoeding, Breda, The Netherlands) if
MOM was not available, containing 2.4 mmol/dL calcium, 1.7 mmol/dL phosphorus and 2.6 grams/dL
proteins. The additional nutrition in ENS A and ENS B was blinded to all caretakers and parents. After
10 days, all infants received nutrition according to the standard protocol of the Radboudumc.
Early supplementation was assumed to provide a high intake (Group High). This group received
enteral nutrition from Day 1 onwards according to the local protocol. They received additional
enteral supplementation and human milk fortifier (Nutrilon Neonatal BMF; Nutricia, Zoetermeer,
The Netherlands; BMF) by the time the enteral intake was 50 mL per day. The human milk fortifier
added 1.65 mmol/dL calcium, 1.22 mmol/dL phosphorus and 0.8 grams/dL protein to human
milk. They received preterm formula if MOM was not available. The decision to start additional
enteral supplementation was left to the attending neonatologist based on biochemical parameter
and postnatal growth as being a standard procedure of our department. The additional enteral
supplementation could comprise of either a supplement of protein (Nutrilon Nenatal Protein Fortifier;
Nutricia, Zoetermeer, The Netherlands) or a potassium phosphate (KPO4) and calcium chloride (CaCl2)
suspension for enteral supplementation.
Group ENS A received 100% human milk during the first 10 days and reflected a group with low
intake of minerals and protein, because human milk has a very low nutrient content. Group High
reflected a high intake of nutrients, because human milk was enriched with minerals and protein as
soon as possible. Group ENS B could be considered as intermediate depending on the amount of
MOM or preterm formula an infant received, since preterm formula contained approximately the same
amount of minerals as fortified human milk.
2.4. Biochemical Parameters of Bone Mineralization
For this study, blood and urine samples were analyzed according to the local protocol of the
department. Samples were taken on Days 1, 3, 5, 7, 10 and 14 after birth. Urine was collected
through spot samples [25]. The following parameters were analyzed: serum calcium (sCa), serum
phosphorus (sP), serum alkaline phosphatase (ALP), urine calcium (uCa), urine phosphorus (uP),
urine calcium/creatinin ratio (uCa/Creat), urine phosphorus/creatinin ratio (uP/Creat), and tubular
reabsorption of phosphorus (TrP).
2.5. Data Registration and Handling
Patient characteristics, clinical course, growth and intake of all nutrients were recorded daily
from the patient records and abstracted for this study. Amounts of enteral, parenteral and additional
supplementation (parenteral and enteral) of all nutrients were calculated separately for each patient.
The total intakes were calculated per kg per day per infant. The intake through human milk was
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calculated based on the reference of Gidrewicz et al. [34]. The calcium/phosphorus ratio was calculated
per day by dividing the daily intake of calcium in mmol/kg through the daily intake of phosphorus
in mmol/kg.
After closure of patient enrollment and de-blinding of the ENS, we performed a reallocation
procedure for the intermediate group ENS B. Infants who received more than 90% MOM were
considered to reflect a low intake of minerals and were allocated to group Low together with the
infants of group ENS A. Infants who received more than 90% of preterm formula were considered to
reflect a high intake of minerals and were allocated to High. Infants in between these extremes were
not included in the analyses.
2.6. Statistical Analysis
The primary objective of the ESS was bone mineralization in relation to mineral supplementation,
and the original power calculation was based on bone mineral content at term corrected age. For the
evaluation of changes in biochemical parameters in relation to nutritional intake the power calculation
was based on sP. In a previous evaluation of our nutritional protocol performed at our department,
we found a mean 1.7 mmol/L of sP during the first week [35]. A concentration of 2.0 mmol/L was
defined as target for optimal bone mineralization by Hellstern et al. [20]. Assuming an expected mean
of 1.7 mmol/L, we determined that 24 infants were required in each group to find a difference of
0.3 mmol/L in sP between High and Low with α = 0.05 (two-sided) and a power of β = 0.80.
The statistical analyses were performed using IBM SPSS statistics 22.0 for Windows (IBM SPSS Inc.,
Chicago, IL, USA). Differences in patient characteristics, nutritional characteristics and biochemical
parameters between the High and Low group were determined using the Mann-Whitney U test
or the chi-square test, depending on the variable under examination. Due to non-normality of the
continuous variables, the data were presented as median (with interquartile range (IQR)), unless
otherwise indicated. A p-value < 0.05 was considered statistically significant.
To account for repeated outcome measurements, we used a mixed model analysis to determine
the effects of daily nutritional intake of calcium and phosphorus on each biochemical parameter.
We included the total intake of Ca/P and protein, the percentage of enteral amount of Ca/P intake, and
a number of clinical parameter that could affect the Ca/P homeostasis such as birth weight, gestational
age, gender, caesarian section, multiple births, sepsis, and days of caffeine, furosemide, steroids, and
sedation during the first two weeks as co-variables in the initial models. Necrotizing enterocolitis was
not included as co-variable because of small numbers. Using manual backward selection, variables
were kept in the model when they contributed statistically significantly with a p-value < 0.1.
3. Results
3.1. Patient Characteristics
Enrollment of patients occurred between January 2013 and December 2014. The distribution of
the infants is presented in the consort diagram (Figure 1). Finally, 109 infants were randomized, either
to Late Supplementation (Low; n = 72; distributed into Group ENS A (n = 40) and ENS B (n = 32) or
Early Supplementation (High; n = 37).
The characteristics of all infants included in the three groups of the ENS/ESS study are presented
in Table A2. After de-blinding of group Low, four infants of group ENS B were reallocated to High and
13 to Low so that Low and High consisted of 53 and 41 infants, respectively. Infants who died or were
discharged before postnatal Day 14 (13 in Low, 11 in High) were excluded. Finally, data of 40 infants of
Low and 30 of High were analyzed. The baseline patient characteristics, morbidity, medication and
nutritional characteristics for these patients are presented in Table 1. Infant characteristics were well
balanced between the groups Low and High and comparable to the original groups.
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Table 1. Patient characteristics, morbidity, medication, and nutritional characteristics.
Low (n = 40) High (n = 30) p-Value
Characteristics
Birth weight, grams; median (IQR) 948 (772–1225) 939 (776–1163) 0.85
<1000 gram, n (%) 22 (55.0) 16 (53.3) 0.89
Gestational age, median (IQR) 28.2 (26.5–29.6) 27.8 (26.1–29.4) 0.76
SGA, n (%) 8 (20.0) 4 (13.3) 0.46
Male, n (%) 19 (47.5) 15 (50.0) 0.84
Singletons, n (%) 28 (70.0) 16 (53.3) 0.15
Cesarean section, n (%) 18 (45.0) 20 (66.7) 0.07
Apgar score (5 min), median (IQR) 7.0 (6.3–9.0) 7.5 (7.0–8.0) 0.71
Apgar score (5 min) <7, n (%) 10 (25.0%) 6 (20.0%) 0.62
Morbidity
Sepsis, n (%) 8 (20.0%) 9 (30.0%) 0.33
NEC ≥ stage 2, n (%) 1 (2.5%) 2 (6.7%) 0.39
IVH Grade 3–4 n (%) 5 (12.5) 3 (10) 0.75
Medication
Caffeïne; n (%) 39 (97.5%) 28 (93.3%) 0.39
Furosemide, n (%) 3 (7.5%) 4 (13.3%) 0.42
Corticosteroids 3 (7.5) 1 (3.3) 0.46
Sedation, n (%) 8 (20.0%) 9 (30.0%) 0.33
Nutritional characteristics
PN, days, median (IQR) 11.0 (9.0–14.0) 12.0 (10.0–14.0) 0.10
150 mL/kg enteral, study day, median (IQR) 12.0 (9.8–17.0) 13.0 (10.5–20.0) 0.59
Start day of BMF, median (IQR) 11 (11.0–13.0) 7.9 (5.0–10.0) 0.00
Human milk in mL/kg/day *, median (IQR) 50.9 (24.0–82.2) 30.0 (8.5–54.6) 0.01
Formula in mL/kg/day *, median (IQR) 0.0 (0.0–0.2) 1.1 (0.1–7.3) 0.00
Nutritional intake
Ca (total) W1, mmol/kg; median (IQR) 10.7 (9.9–12.0) 13.1 (11.1–14.6) 0.00
Ca (total) W2, mmol/kg; median (IQR) 16.4 (12.9–17.7) 21.7 (15.3–24.4) 0.00
P (total) W1, mmol/kg; median (IQR) 10.8 (9.3–12.4 12.3 (11.1–14.2) 0.00
P (total) W2, mmol/kg; median (IQR) 16.4 (12.9–19.6) 18.2 (16.0–22.1) 0.02
Prot (total) W1, grams/kg; median (IQR) 18.6 (15.9–21.1) 20.0 (16.9–23.4) 0.16
Prot (total) W2, grams/kg; median (IQR) 23.2 (21.0–26.6) 27.0 (24.1–30.6) 0.00
Low: no enteral supplementation of human milk before Day 11; High: standard protocol: enteral
supplementation of human milk if intake was ≥50 mL/day; IQR: Interquartile range; SGA: small for
gestational age: <p10; Sepsis: >72 h postnatally and positive blood culture, prevalence within the first
14 days; NEC: necrotizing enterocolitis according to Bell stage [36], prevalence within the first 14 days;
IVH: Intraventricular hemorrhage (grade according to Papile) [37]; PN: parenteral nutrition; BMF: breast
milk fortifier; *: during the intervention period; Ca: calcium; P: phosphorus; Prot: protein; W1: Week 1; W2:
Week 2.
3.2. Nutritional Intake
The nutritional characteristics and intake of calcium, phosphorus and protein during Weeks 1
and 2 are presented in Table 1. The median and interquartile range (IQR) for the duration of PN was
12.0 (10.0–14.0) versus 11.0 (9.0–14.0) days for High versus Low, while the median day of reaching
an enteral intake of 150 mL/kg was Day 13.0 (10.5–20.0) versus Day 12.0 (9.8–17.0), respectively.
In accordance with the study protocol, Low received a higher amount of human milk. The median
start day of BMF in groups High and Low was 7.9 (5.0–10.0) and 11.0 (11.0–13.0) respectively. As a
result, High received a significant higher total intake of calcium and phosphorus during the first
two weeks and of protein during Week 2 compared to Low. Table A3 presents the nutritional intake
divided into four routes of administrations: parenteral, enteral and additional supplementation either
par- or enteral. This shows that differences in intake were mainly based on differences in enteral intake.
Further, both groups received additional parenteral supplementation of phosphorus, based on low
sP concentrations.
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Figure 2 presents the daily changes in nutritional intake during the first 14 days. Figure 2A,B,D
demonstrate the total calcium, phosphorus and protein intake. High had a steady increase in
intake during the study period, whereas Low showed a temporary decrease, and plateau at the
end of the observational period, probably due to the decreasing amount of PN and increasing
amount of unfortified human milk. Except for Day 1, both groups received a median total calcium,
phosphorus and protein intake according to the ESPGHAN recommendations for parenteral and
enteral nutrition [38,39]. The calcium/phosphorus ratios were highly variable. Both groups showed a
decrease in the calcium/phosphorus ratio on Day 5 that lasted until Day 11 (Figure 2C), most likely
caused by the transition from parenteral nutrition to enteral nutrition. For both groups, the ratio was
below the recommendations of ESPGHAN on all days [38,39].
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3.3. Biochemical Parameters
Table A4 summarizes the median daily values of both groups for all biochemical parameters.
The median serum concentrations of Ca en P were within the normal range and only showed slight
differences between the two groups and an overall increase during the study period [40]. Except for
the first day, the median sP concentrations remained below our targe f 2 mmol/L until Days 5 and 10
for High and Low, respectively. The median uCa and P values were above the recommended surplus
(uCa > 1.2 mmol/L, uP > 0.4 mmol/L) during the entire observational period [23]. The median TrP
values were above the lower normal range of 85% until Day 5, and decreased thereafter, reflecting a
higher loss of phosphorus. The median ALP values were within the normal range (80–330 U/L) until
Day 5, but increased steadily thereafter [40]. In both groups, the uCa/Creat ratios were above the
reference value (0.5 mmol/mmol) during the complete study period [32]. The uP/Creat ratios were
below the reference value (4.0 mmol/mmol) until Day 5, but above the reference thereafter [32].
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The results of the mixed model analyses are summarized in Table 2.
• The sCa concentration was not related to intake of Ca/P and was only marginally affected by a
number of co-variables except for daily protein intake that caused an increase of 0.107 mmol/L
per gram/kg protein.
• The sP concentration increased in relation to phosphorus intake (0.13 mmol/L per mmol/kg
phosphorus) and birth weight (0.0004 mmol/L per gram birth weight), whereas protein intake
(−0.13 mmol/L per gram/kg/day protein), gestational age (−0.05 mmol/L per week), furosemide
(−0.11 mmol/L per day) and caffeine (−0.02 mmol/L per day) decreased in sP concentration.
• The urinary excretion of Ca seemed to increase in relation to Calcium intake (0.35 mmol/L per
mmol/kg calcium), and increased in relation to protein (0.36 mmol/L per gram/kg protein) and
being born by cesarean section (0.65 mmol/L if born by cesarean section), whereas it was not
affected by the phosphorus intake.
• The urinary excretion of P increased in relation to daily phosphorus intake (3.18 mmol/L per
mmol/kg phosphorus) and gender (1.88 mmol/L if infant was a boy), whereas P excretion
lowered in relation to daily intake of protein (−1.18 mmol/L per mmol/kg protein), gestational
age (−0.71 mmol/L per week) and caffeine (−0.29 mmol/L per day). Calcium intake did not
affect the urinary P excretion.
• The TrP increased in relation the daily Calcium intake (3.10% per mmol/kg calcium) and
gestational age (3.05% per week). The reabsorption of phosphorus lowered in relation to daily
phosphorus intake (−6.21% per mmol/kg phosphorus), gender (−4.60% if infant was a boy),
being born by cesarean section (−5.12%), and sepsis (−6.78%).
• The ALP increased in relation protein intake (30.54 U/L per mmol/kg) and daily intake of
phosphorus (23.64 U/L per mmol/kg phosphorus). A decrease in ALP was related to calcium
intake (−44.94 U/L per mmol/kg calcium), gestational age (−20.71 U/L per week) and the
number of days of steroid use (−23.86 U/L per day).
• The uCa/creat ratio increased in relation to daily protein intake (0.54 L/L per gram/day protein)
and sepsis (0.66 L/L), but it was not affected by the total calcium and phosphorus intake.
• The uP/creat ratio increased in relation to daily phosphorus intake (4.01 L/L per mmol/kg
phosphorus), gender (2.31 L/L if infant was a boy), while the P/creat ratio seemed lower in
relation to daily protein intake (−0.81 L/L per gram/kg protein), and decreased with gestational
age (−0.94 L/L per week), and caffeine (−0.30 L/L per day).
Table 2. Mixed Model analysis: Effect of nutritional intake and clinical characteristics on
biochemical parameter.
Dependant Variable Covariates Estimate 95% CI p-Value
Serum Calcium Total intake of Ca (mmol/kg/day) 0.004 −0.046–0.054 0.89
Total intake of P (mmol/kg/day) −0.036 −0.073–0.002 0.06
Enteral intake of P (%) 0.001 −0.000–0.001 0.06
Intake of protein (grams/kg /day) 0.107 0.075–0.139 0.00
Gestational age (weeks) 0.027 0.013–0.042 0.00
Singleton (yes) 0.081 0.021–0.140 0.01
Sepsis (yes) −0.092 −0.167–−0.019 0.02
Sedation (days) −0.007 −0.016–0.001 0.07
Serum Phosphorus Total intake of Ca (mmol/kg/day) 0.0345 −0.0473–0.1164 0.41
Total intake of P (mmol/kg/day) 0.1252 0.0586–0.1918 0.00
Enteral intake of Ca (%) 0.0035 0.0023–0.0048 0.00
Intake of protein (grams/kg/day) −0.1274 −0.1825–−0.0723 0.00
Birth weight (grams) 0.0004 0.0002–0.0006 0.00
Gestational age (weeks) −0.0479 −0.0701–−0.0258 0.00
Gender (boy) −0.0698 −0.1493–0.096 0.08
Caffeine (days) −0.0215 −0.0354–−0.0075 0.00
Furosemide (days) −0.1116 −0.2029–−0.0203 0.02
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Table 2. Cont.
Dependant Variable Covariates Estimate 95% CI p-Value
Urine Calcium Total intake of Ca (mmol/kg/day) 0.35 0.01–0.70 0.05
Total intake of P (mmol/kg/day) −0.01 −0.29–0.27 0.94
Enteral intake of Ca (%) −0.02 −0.02–−0.01 0.00
Intake of protein (grams/kg/day) 0.36 0.12–0.61 0.00
Cesarean section (yes) 0.65 0.32–0.98 0.00
Urine Phosphorus Total intake of Ca (mmol/kg/day) −0.05 −1.56–1.45 0.94
Total intake of P (mmol/kg/day) 3.18 2.06–4.30 0.00
Enteral intake of P (%) 0.07 0.04–0.09 0.00
Intake of protein (grams/kg/day) −1.18 −2.20–−0.16 0.02
Gestational age (weeks) −0.71 −1.09–−0.33 0.00
Gender (boy) 1.88 0.26–3.50 0.02
Caffeine (days) −0.29 −0.54–−0.01 0.04
Tubular reabsorption of P Total intake of Ca (mmol/kg/day) 3.10 0.160–6.04 0.04
Total intake of P (mmol/kg/day) −6.21 −8.78–−3.65 0.00
Enteral intake of P (%) −0.09 −0.15–−0.03 0.01
Gestational age (weeks) 3.05 1.92–4.17 0.00
Gender (boy) −4.60 −9.22–0.01 0.05
Cesarean section (yes) −5.12 −9.95–−0.29 0.04
Sepsis (yes) −6.78 −12.72–−0.85 0.03
Furosemide (days) 4.75 −0.53–10.03 0.07
Alkaline Phosphatase Total intake of Ca (mmol/kg/day) −44.94 −69.51–−20.37 0.00
Total intake of P (mmol/kg/day) 23.64 4.14–43.14 0.02
Enteral intake of Ca (%) 2.07 1.69–2.45 0.00
Intake of protein (grams/kg/day) 30.54 14.08–47.01 0.00
Gestational age (weeks) −20.71 −30.37–−11.05 0.00
Postnatal steroids (days) −23.86 −44.29–−3.43 0.02
Urine Ca/Crea ratio Total intake of Ca (mmol/kg/day) 0.138 −0.292–0.568 0.53
Total intake of P (mmol/kg/day) 0.139 −0.204–0.481 0.43
Enteral intake of Ca (%) −0.023 −0.029–−0.016 0.00
Intake of protein (grams/kg/day) 0.497 0.206–0.787 0.01
Sepsis (yes) 0.584 0.003–1.166 0.05
Urine P/Crea ratio Total intake of Ca (mmol/kg/day) −1.10 −2.51–0.31 0.12
Total intake of P (mmol/kg/day) 4.01 2.97–5.05 0.00
Enteral intake of P (%) 0.06 0.04–0.08 0.00
Intake of protein (grams/kg/day) −0.81 −1.76–0.14 0.10
Gestational age (weeks) −0.94 −1.32–−0.55 0.00
Gender (boy) 2.31 0.72–3.89 0.01
Sepsis (yes) 1.72 −0.24–3.68 0.09
Caffeine (days) −0.30 −0.56–−0.03 0.03
sCa: serum calcium (mmol/L); uCa: urine calcium (mmol/L); sP: serum phosphorus (mmol/L); uP: urine
phosphorus (mmol/L); TrP: tubular reabsorption of phosphorus (%); ALP: Alkaline phosphatase (U/L);
uCa/Crea ratio: urine calcium/creatinin ratio (mmol/mmol); uP/Crea ratio: urine phosphorus/creatinine ratio
(mmol/mmol); 95% CI: 95% confidence interval; Co-variables initially included: daily nutritional intake of
calcium, phosphorus, and protein, the enteral amount of calcium and phosphorus intake, caesarian section,
multiple births, birth weight, gestational age, gender, necrotizing enterocolitis, sepsis, caffeine, furosemide,
steroids and sedation.
4. Discussion
In this observational study of initially three randomized groups providing different nutritional
intake to VLBW infants during the first 10 days of life, we found no differences between groups
Low and High concerning the biochemical parameters of Ca-P homeostasis. However, the mixed
model analysis showed that the intake of calcium was associated with increased urinary calcium
excretion and tubular reabsorption of phosphorus and a decrease in the ALP, while the nutritional
intake of phosphorus was associated with a decreased sCa and an increase in sP, uP and uP/creat ratio.
The nutritional intake of calcium and phosphorus affected the TrP and ALP in opposite directions.
Protein intake was greatly associated with a decrease in sP, uP and an increase in ALP, sCa, and uCa,
while, in addition, gestational age and male gender affected especially the phosphorus metabolism.
VLBW infants belong to one of the most vulnerable patient groups for whom adequate postnatal
nutritional intake has life-long consequences [41]. Therefore, intervention studies with different
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nutritional intakes could be seen as unethical in the light of the right of optimal treatment for every
patient. On the other hand, in clinical practice a great variation in clinical guidelines has been reported,
often based on rather low evidence [42]. While fortification of human milk is generally seen as necessary
nowadays, there is also concern about possible risks of introducing cow-milk based products too
early [43,44]. According to our local protocol, fortification is introduced early and additional mineral
supplementation is provided based on laboratory results. The intention is to optimize postnatal growth
and bone mineralization but the efficacy of our protocol has not been proven. The combination of the
Early Nutrition Study and the Early Supplementation Study provided the opportunity to evaluate
two different nutritional concepts within the range of nutritional guidelines and therefore within the
ethical limits. On the other hand, all infants participating in the ESS, independent of group allocation,
received the standard treatment according to the local practice, which frequently led to additional
parenteral supplementation of nutrients in case of electrolyte disturbances or impaired growth. This
practice may have ameliorated the differences between the groups and therefore affected the results.
By reallocating infants from group ENS B to either group Low or High and excluding infants with
intermediate intake from further analysis, we tried to maximize the differences in nutritional intake
between the two remaining groups. The reallocation of infants did not change the baseline patient
characteristics. The detailed analysis of nutritional intake showed that additional supplementation
was not different between the groups and differences in intake were mainly based on enteral nutrition.
Even though the two groups had a maximum difference in nutritional intake, the comparison of
daily concentrations of the biochemical parameters showed no differences between groups High and
Low, probably by leveling out inter-individual differences on group level. In contrast, the linear mixed
model analysis took into account both intra- and inter-individual fluctuations, and thereby enabled us
to specify effects of various co-variables.
Despite an increasing intake of phosphorus, sP remained below our target concentration during
the first week. Recently, a randomized trial, evaluating nutritional support according to current
recommendations in VLBW infants, observed hypophosphatemia in relation to high protein intake [45].
Jamin et al. observed electrolyte disturbances, especially hypophosphatemia and hypokalemia, in
low-birth weight piglets with a high protein diet [46]. Hypophosphatemia is the hallmark of the
refeeding syndrome and a well-known complication in relation to parenteral nutrition of malnourished
patients [47–49]. Bonsante et al. proposed the concept of Placental Incompletely Restored Feeding
(PI-Refeeding) syndrome for electrolyte disturbances found in VLBW infants [50]. This syndrome is
said to be caused by an imbalanced nutritional intake of amino acids and phosphorus. Amino acids and
energy are needed to maintain an anabolic state of the cell, while phosphorus is necessary for a number
of cellular functions, energy homeostasis as well as for bone mineralization. Phosphorus in blood will
preferably be transferred to the cell regardless of bone mineral status. A higher intake of amino acids
will enhance the need for phosphorus in growing cells, and in case of low concentrations of phosphorus
in blood it will be released from bone. Simultaneously with the release of phosphorus, calcium will
also be released from the bone because of an unfavorable Ca/P ratio and will consecutively be excreted
in urine if the sP concentrations are too low. Our results are in agreement with this concept. According
to the mixed model analyses, we found that an increasing amount of protein was associated with an
increase in the sCa, uCa, ALP and uCa/Creat ratio, whereas it was associated with a decrease in sP, uP
and the uP/Creat ratio. Remarkably, in our study, an increase in a sP concentration of 0.13 mmol/L
occurred per 1 mmol/kg intake of phosphorus and a decrease of−0.13 mmol/L per 1 gram/kg protein
intake, meaning that 1 gram/kg of protein intake should be accompanied by 1 mmol/kg of phosphorus
in nutrition of VLBW infants to maintain adequate sP concentrations.
The role of ALP in bone mineralization is controversial, but an increase is usually associated
with poor bone mineralization [30,51]. According to our results, an increasing intake of protein was
associated with an increase in ALP. Again, following the above mentioned mechanisms higher protein
intake enhanced the cellular need of phosphorus and thereby decreased the sP concentration and
the availability of phosphorus for bone mineralization, leading to activation of ALP. We also found
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that an increased ALP was associated with increasing phosphorus intake, while one would expect
lowering of ALP. An explanation for this phenomenon could be a relatively insufficient intake of
calcium in combination with phosphorus intake, since an increasing calcium intake was associated
with decrease in ALP concentrations. In this study, for both groups, the calcium/phosphorus ratio was
below recommendations, meaning that relatively more phosphorus than calcium was administered.
Gestational age at birth seemed to be an important determinant for the phosphorus metabolism
in our study, meaning that infants with a lower gestational age had a higher renal excretion of
phosphorus, irrespective of nutritional intake. Immaturity of the kidneys at lower gestational age
has been shown to cause impaired tubular reabsorption of phosphorus [15]. Renal losses of minerals
may then compromise the effect of nutritional intake on bone mineralization. However, current
recommendations for nutritional intake of calcium and phosphorus usually do not take into account
differences in renal function based on gestational age.
Further, we found that male gender was related to low serum phosphorus concentrations, low
tubular reabsorption and increased renal excretion of phosphorus and uP/creat ratio. We speculate a
retardation in maturation of the renal function in male infants compared to females as is known for the
development of the pulmonary function [52].
All parameters evaluated in this study are regularly used to monitor either electrolyte homeostasis
or bone mineralization. Practices among units vary greatly, measurements may be performed at later
age and greater intervals and not standardized or in combination, leading to inconsistent results and
handling. An explanation for the inconsistency in results of other studies could be the underestimation
of the effects of inter-relationships between various co-variates. In our opinion, these associations
can only be discovered with standardized repeated measurements taking into account other clinical
factors. To our knowledge, this is the first study evaluating changes in biochemical parameters of the
calcium-phosphorus homeostasis based on standardized repeated measurements and daily changes in
nutritional intake in a mixed model linear regression analysis including also clinical factors.
Our data show that standardized repeated measurements of blood and urine samples can provide
useful information with regard to the Ca-P homeostasis. This does not result in a clear advice for
nutritional intake. Nevertheless, this study is a first step and its importance lies in the description
and quantification of changes in a more “physiological way” that will further enable us to develop
new guidelines to improve bone mineral status in preterm infants. Notwithstanding, we confirmed
the relationship between the intake of protein and phosphorus, and demonstrated the effect of renal
immaturity and gender. Thus, a second step could be, to relate the current results to bone mineralization
and provide recommendations for nutritional intake and a third step to develop a concept of target
values for biochemical parameter so that these can be used to monitor nutritional intake to achieve
optimal bone mineralization in daily practice.
This study had several limitations. The mixed model analysis assumes that the effects of the
different variables are linear which has not been proven yet. In addition, the biochemical parameters
may have been influenced by factors that were not taken into account in our analysis. Daily sampling
of biochemical parameter would have been optimal, but this was judged unethical regarding the
amount of blood volume needed. Nevertheless, measurements were performed in a standardized
manner and therefore provided a good reflection of changes in blood and urine concentrations for
the complete study period. Further, in comparison to other studies, both groups had relatively high
daily intakes. This may partly explain the small variations in biochemical parameters. This study
only investigated the biochemical parameters during the first 14 days of life. Maturational changes in
renal function may alter the results; however, repeated measurements will indicate these changes and
thereby can be used as guide for optimal supplementation of minerals.
5. Conclusions
In conclusion, standardized repeated measurements showed that biochemical parameters of
Ca-P homeostasis seemed to be affected by nutritional intake of calcium and phosphorus as well
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as protein, while immaturity of kidneys was related to an increase in urinary excretion of minerals
irrespective of nutritional intake. Further studies are needed to define target values to stabilize
electrolyte balances and improve bone mineralization taking into account nutritional intake and
gestational age of the patient.
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Appendix
Table A1. Standard parenteral nutritional intake.
Day 1 Day 2 Day 3 Day 4
Fluid mL/kg/day 80 100 125 150
CH grams/kg/day 8 9.6 11.7 13.8
AA grams/kg/day 0.75 1.5 2.25 3
Lipids grams/kg/day 1 2 3 3
EQ Kcal/kg/day 44 62 82 94
Calcium mmol/kg/day 0.75 1.5 2.25 3.00
Phosphorus mmol/kg/day 0.48 0.96 1.44 1.92
Parenteral nutritional intake based on standardized parenteral solutions [35,53]. For infants below 1000 grams,
amino acids were additionally added according to current recommendations [12]. Amino acid solution: Primene
(Baxter, the Netherlands); Lipid emulsion including vitamins: Clinoleic (20%; Baxter, The Netherlands) or
SMOFlipid 20% (Fresenius Kabi; The Netherlands); CH: carbohydrates, AA: amino acids, EQ: energy quotient.
Table A2. Cohort characteristics of all patients included in the Early Supplementation Study.
Characteristics Group ENS A (n = 40) Group ENS B (n = 32) Group C (n = 37)
GA, weeks; med (IQR) 28.2 (25.7–30.1) 28.3 (26.5–30.7) 27.9 (26.1–29.7)
Birth weight, grams; med (IQR) 967 (753–1245) 1012 (847–1199) 1006 (771–1220)
SGA; n (%) 9 (23) 8 (25) 6 (16)
Male; n (%) 21 (53) 20 (63) 18 (49)
Singletons; n (%) 25 (63) 24 (74) 25 (68)
Antenatal Steroids compl.; n (%) 36 (90) 31 (97) 31 (86)
Cesarean section; n (%) 19 (48) 20 (63) 25 (68)
Apgar score (5 min); med (IQR) 7.5 (6.3–9.0) 8.0 (7.0–9.0) 7.0 (7.0–8.0)
Apgar score (5 min) <7; n (%) 10 (25) 5 (16) 8 (22)
Mortality; n (%) 6 (15) 3 (9) 7 (19)
Morbidity
IRDS 24 (60) 19 (59) 23 (62)
Days of MV; med (IQR) 1.5 (0.0–4.8) 1.0 (0.0–4.0) 1.0 (0.0–7.0)
Days of N-CPAP; med (IQR) 18.0 (6.5–38.8) 28.0 (7.0–40.8) 16.0 (6.0–36.5)
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Table A2. Cont.
Characteristics Group ENS A (n = 40) Group ENS B (n = 32) Group C (n = 37)
CLD; n (%) 12 (30) 14 (44) 10 (27)
PDA; n (%) 20 (50) 20 (63) 21 (57)
Ductal ligation; n (%) 4 (10) 2 (6.3) 1 (3)
IVH grade ≤ 2; n (%) 15 (38) 5 (16) 5 (14)
IVH grade ≥ 3; n (%) 2 (5) 7 (21) 4 (11)
Sepsis; n (%) 13 (33) 10 (32) 14 (38)
NEC; n (%) 4 (10) 5 (16) 3 (8)
Bell stage 2; n 2 3 1
Bell stage 3; n 2 2 2
Laparotomy; n 2 1 2
ROP; n (%) 4 (10) 1 (3) 5 (14)
ROP grade ≥ 3 1 0 1
Medication
Caffeine; n (%) 38 (95) 30 (94) 33 (90)
Furosemide; n (%) 11 (28) 10 (31) 7 (19)
Diuretics (maintenance); n (%) 3 (8) 0 3 (8)
Corticosteroids; n (%) 1 (3) 2 (6) 4 (11)
Sedation; n (%) 13 (33) 11 (34) 15 (41)
Nutritional characteristics
Days of PN; med (IQR) 10.0 (8.0–13.0) 10.5 (9.0–14.8) 10.5 (8.3–21.0)
120 mL/kg enteral, day; med (IQR) 9.0 (7.0–12.5) 9.0 (8.0–13.0) 9.0 (7.2–14.8)
150 mL/kg enteral, day; med (IQR) 12.0 (9.0–17.0) 11.0 (10.0–17.0) 12.0 (10.0–20.0)
Start day of BMF; med (IQR) 11.0 (11.0–12.7) 12.0 (11.0–14.0) 6.0 (4.0–8.0)
ENS A: donor milk in addition to mother’s own milk (MOM) and no supplements with enteral feeding
until Day 10; ENS B: preterm formula in addition to MOM and no supplements with enteral feeding until
Day 10; Group C: preterm formula in addition to MOM and fortifier if intake ≥50 mL/day; med: median;
IQR: inter quartile range; GA: gestational age; SGA: small for gestational age according to Fenton et al. [54];
IRDS: infant respiratory distress syndrome; MV: mechanical ventilation; N-CPAP: nasal continuous positive
airway pressure; CLD: chronic lung disease defined as oxygen dependency at 36 weeks gestational age; PDA:
patent ductus arteriosus with need for treatment; IVH: intra-ventricular hemorrhage; Sepsis: >72 h postnatally
and positive blood culture; NEC: necrotizing enterocolitis with staging according to Bell [36]; ROP: retinopathy
of prematurity; sedation: morfine and/or midazolam >24 h; PN: parenteral nutrition; BMF: breast milk fortifier.
Table A3. Nutritional intake of calcium and phosphorus by route of administration.
Nutritional Intake (mmol/kg/Week) Low (n = 40) Median (IQR) High (n = 30) Median (IQR) p-Value
Ca (total) W1 10.7 (9.9–12.0) 13.1 (11.1–14.6) 0.00
Ca (total) W2 16.4 (12.9–17.7) 21.7 (15.3–24.4) 0.00
Ca (enteral) W1 1.7 (1.1–2.2) 3.3 (1.1–5.7) 0.00
Ca (enteral) W2 10.8 (6.2–16.0) 17.5 (2.3–22.8) 0.07
Ca (enteral suppl) W1 0.0 (0.0–0.0) 0.0 (0.0–0.0) 1.0
Ca (enteral suppl) W2 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.22
Ca (PN) W1 9.4 (8.0–10.2) 9.8 (7.9–11.5) 0.34
Ca (PN) W2 3.1 (0.7–7.9) 5.1 ( 1.9–10.9) 0.14
Ca (PNsuppl) W1 0.0 (0.0–0.0) 0.0 (0.0–0.0) 1.0
Ca (PNsuppl) W2 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.74
P (total) W1 10.8 (9.2–12.4) 12.3 (11.1–14.2) 0.00
P (total) W2 16.4 (12.9–19.6) 18.9 (16.0–22.1) 0.02
P (enteral) W1 1.0 (0.6–1.4) 2.1 (0.7–3.9) 0.00
P (enteral) W2 8.1 (5.0–12.0) 10.4 (1.7–17.2) 0.08
P (enteral suppl) W1 0.0 (0.0–0.0) 0.0 (0.0–0.9) 0.03
P (enteral suppl) W2 0.0 (0.0–0.0) 0.0 (0.0–1.4) 0.33
P (PN) W1 7.5 (6.4–8.2) 7.8 (6.3–9.2) 0.34
P (PN) W2 2.5 (0.6–6.3) 4.1 (1.5–8.7) 0.14
P (PN suppl) W1 2.4 (0.5–3.8) 1.8 (0.0–2.7) 0.16
P (PN suppl) W2 2.3 (0.0–4.2) 0.7 (0.0–4.3) 0.30
Low: no enteral supplementation of human milk before Day 11; High: standard protocol: enteral
supplementation of human milk if intake was ≥50 mL/day; IQR: inter quartile range; Ca: calcium;
P: phosphorus; total: som of all nutritional intake; enteral: enteral intake including standard fortification;
enteral suppl: additional enteral supplementation; PN: parenteral intake; PN suppl: additional parenteral
supplementation; W1: week 1; W2: week 2.
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Table A4. Daily measurements of biochemical parameter of the calcium and phosphorus homeostasis.
Day 1 Day 3 Day 5 Day 7 Day 10 Day 14
Serum Ca (mmol/L)
Low 2.2 (2.0–2.4) 2.4(2.2–2.5) 2.5 (2.4–2.7) 2.6 (2.4–2.7) 2.5 (2.4–2.7) 2.6 (2.4–2.8)
High 2.2 (2.0–2.4) 2.4 (2.3–2.6) 2.5 (2.4–2.7) 2.4 (2.3–2.6) 2.5 (2.3–2.7) 2.6 (2.5–2.8)
p-Value 0.94 0.17 0.34 0.15 0.69 0.17
Urine Ca (mmol/L)
Low 1.3 (1.0–1.9) 2.1 (1.5–3.4) 2.6 (2.0–3.9) 2.7 (1.6–3.8) 2.0 (1.6–3.3) 1.8 (1.4–3.5)
High 1.5 (1.2–1.7) 3.3 (2.0–4.7) 3.1 (2.3–5.8) 2.5 (1.8–3.8) 2.7 (2.0–3.4) 2.3 (1.6–3.4)
p-Value 0.66 0.03 0.06 0.84 0.21 0.50
Serum P (mmol/L)
Low 1.8 (1.7–2.2) 1.8 (1.5–2.0) 1.7 (1.5–2.0) 1.9 (1.8–2.2) 2.0 (1.8–2.2) 2.3 (2.1–2.4)
High 2.1 (1.8–2.3) 1.8 (1.5–2.0) 1.6 (1.3–2.2) 2.1 (1.8–2.4) 2.1 (2.0–2.4) 2.2 (2.0–2.3)
p-Value 0.22 0.88 0.71 0.21 0.08 0.16
Urine P (mmol/L)
Low 1.7 (0.3–3.8) 2.1 (0.7–5.5) 1.3 (0.7–3.5) 4.1 (0.7–6.8) 5.4 (2.2–8.2) 10.4 (6.8–18.4)
High 2.3 (0.2–4.6) 2.6 (0.9–4.1) 3.1 (1.6–6.9) 5.4 (3.5–9.8) 7.4 (4.5–13.7) 9.5 (5.5–16.4)
p-Value 0.68 0.98 0.04 0.02 0.04 0.46
Tubular reabsorption of P (%)
Low 94.0 (76.8–98.2) 86.5 (76.1–95.3) 92.2 (83.8–96.9) 83.1 (72.4–96.3) 80.8 (68.8–92.7) 75.9 (64.9–85.2)
High 85.3 (76.4–98.1) 92.7 (73.3–95.7) 88.1 (80.8–95.1) 79.4 (51.9–87.6) 76.6 (59.1–83.2) 67.4 (53.9–82.4)
p-Value 0.59 0.62 0.21 0.08 0.23 0.36
Alkaline Phosphatase (U/L)
Low 167.0 (138.0–236.0) 213.0 (182.0–291.0) 263.5 (202.3–368.5) 329 (261.3–455.0) 379 (311.0–503.0) 423.0 (301.8–506.0)
High 203 (146.5–232.8) 244.0 (174.3–270.8) 275.5 (206.3–307.0) 304.5 (249.3–375.0) 342.0 (213.8–414.3) 380.0 (281.8–509.8)
p-Value 0.76 0.94 0.76 0.22 0.10 0.66
uCa/Crea ratio (mmol/mmol)
Low 2.1 (1.3–3.5) 2.5 (1.8–3.1) 3.6 (2.3–5.2) 3.8 (2.3–6.2) 2.9 (1.8–4.1) 2.3 (1.6–3.7)
High 1.7 (1.4–3.7) 2.7 (2.0–6.1) 4.0 (2.9–6.3) 3.0 (2.1–5.4) 3.8 (2.4–5.0) 3.4 (1.9–4.8)
p-Value 0.98 0.30 0.35 0.49 0.21 0.14
uP/Crea ratio (mmol/mmol)
Low 1.6 (0.5–5.9) 2.8 (1.0–6.8) 1.9 (0.8–5.4) 5.1 (1.1–9.3) 7.2 (2.5–12.3) 11.2 (6.2–18.6)
High 3.8 (0.5–6.7) 1.8 (1.1–5.8) 3.5 (1.6–6.1) 7.7 (5.0–10.9) 9.4 (7.0–16.5) 14.5 (9.3–18.7)
p-Value 0.64 0.72 0.15 0.14 0.06 0.73
All data are presented as median and interquartile range; sCa: serum calcium (mmol/L); uCa: urine calcium (mmol/L); sP: serum phosphorus (mmol/L); uP: urine
phosphorus (mmol/L); TrP: tubular reabsorption of phosphorus (%); ALP: Alkaline phosphatase (U/L); uCa/Crea ration: urine calcium/creatinine ration (mmol/mmol); uP/Cre
ratio (mmol/mmol).
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